JP Morgan Chase
ARTV

JP Morgan Chase’s Artiva Biotherapeutics ARTV Stock Holding History

JP Morgan Chase’s Portfolio ARTV Stock Details ARTV Fund Activity
Bought
Maintained
Sold
Quarter Market Value Status Shares Change in
Stake 		Trade Value Portfolio Weight Portfolio Position
2026
Q1 		$1.22K Buy
223
+36
+19% +$178 ﹤0.01% 7098
2025
Q4 		$802 Sell
187
-3,815
-95% -$14.4K ﹤0.01% 7041
2025
Q3 		$11.5K Buy
4,002
+3,137
+363% +$8.39K ﹤0.01% 6604
2025
Q2 		$1.31K Sell
865
-17,018
-95% -$35.7K ﹤0.01% 6596
2025
Q1 		$53.6K Sell
17,883
-19,736
-52% -$107K ﹤0.01% 5856
2024
Q4 		$379K Buy
37,619
+26,893
+251% +$323K ﹤0.01% 5180
2024
Q3 		$166K Buy
+10,726
New +$124K ﹤0.01% 5493

Other funds holding ARTV

RCM
RA Capital Management Boston, Massachusetts $9.44B AUM 157.3% 1-Year Est. Return
5VM
5AM Venture Management San Francisco, California $360M AUM 345.76% 1-Year Est. Return
VA
VR Adviser New York $2.68B AUM 422.73% 1-Year Est. Return
VP
venBio Partners San Francisco, California $281M AUM 261.03% 1-Year Est. Return
Franklin Resources
Franklin Resources San Mateo, California $408B AUM 30.18% 1-Year Est. Return
RCM
Revelation Capital Management Sausalito, California $67.4M AUM
BlackRock
BlackRock New York $5.72T AUM 30.48% 1-Year Est. Return
VCM
Vanguard Capital Management Malvern, Pennsylvania $4.04T AUM
Wellington Management Group
Wellington Management Group Boston, Massachusetts $535B AUM 26.23% 1-Year Est. Return
PBM
Propel Bio Management Los Angeles, California $159M AUM 60.94% 1-Year Est. Return

JP Morgan Chase's ARTV Position: Q1 2026 in Review

JP Morgan Chase increased its Artiva Biotherapeutics (ARTV) stake by 19% in Q1 2026, buying an estimated $178 and bringing the position to 223 shares worth $1.22K. The position accounts for ﹤0.01% of the portfolio, ranked #7098.

JP Morgan Chase first reported a position in ARTV in Q3 2024 and has held it in 7 quarters since. The position peaked at $379K in Q4 2024. 40 funds tracked by Wall St. Rank hold ARTV as of Q1 2026.

  • JP Morgan Chase held 223 shares of Artiva Biotherapeutics worth $1.22K as of Q1 2026.
  • JP Morgan Chase bought 36 Artiva Biotherapeutics shares in Q1 2026, an estimated $178.
  • Artiva Biotherapeutics made up ﹤0.01% of JP Morgan Chase's portfolio in Q1 2026, its #7098 holding.
  • JP Morgan Chase first reported a position in Artiva Biotherapeutics in Q3 2024 and has held it in 7 quarters since.
  • JP Morgan Chase's Artiva Biotherapeutics position peaked at $379K in Q4 2024.
  • 40 funds tracked by Wall St. Rank held Artiva Biotherapeutics as of Q1 2026.

Based on JP Morgan Chase's 13F filing for Q1 2026, filed 13 May 2026.